MedTrace Logo

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-11-24

No results posted yet for this study

Summary

This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.

Conditions

  • Macula Edema
  • Radiation Retinopathy
  • Branch Retinal Vein Occlusion
  • Epiretinal Membrane
  • Central Serous Retinopathy With Pit of Optic Disc
  • Commotio Retinae
  • Vitritis

Interventions

DRUG

Episcleral Celecoxib

Sustained Release Transscleral Celecoxib

Sponsors & Collaborators

  • Targeted Therapy Technologies, LLC

    lead INDUSTRY

Principal Investigators

  • Theodore Leng, MD · Stanford Medicine Ophthalmology [Recruiting]

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2024-06-30
Completion
2024-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04120636 on ClinicalTrials.gov